Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

nivolumab

nivolumab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Opdivo Qvantig INJECTION, SUBCUTANEOUS 120 mg-2,000 units/mL      
Opdivo SOLUTION, INTRAVENOUS 10 mg/mL      
VIEW MORE Antineoplastic Agents
CLASS
100000
Comments:

Opdivo: Indicated for resistant cases of melanoma and NSCLC, given IV every 2 weeks. Defer to outpatient setting if possible.  Rare inpatient use expected.

 

Opdivo Qvantig: Restricted to oncologist use in the outpatient setting.

 

For Updated Formulary Preferred Products (Inpatient and Outpatient): Preferred Products for Select Agents 

 

Opdivo medication guide

Reviewed: 25 August 2015 (Opdivo), February 2026 (Opdivo Qvantig)

Nivolumab_hyaluronidase-nvhy (OPDIVO QVANTIG) Spotlight.pdf

Last updated: Mar. 17, 2026






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved